Negative findings from trials with NLY01 or deferiprone for Parkinson's disease.

Thomas Müller, Jan Dominique Möhr

Journal: The Lancet. Neurology 2024;23(6):558-559

PMID: 38760091

Full Text on Elsevier Science View on PubMed

Abstract

Address: Department of Neurology, St Joseph Hospital Berlin-Weissensee, 13088 Berlin, Germany. Electronic address: [email protected].; Department of Internal Medicine, St Elisabeth Hospital, Ruhr University of Bochum, Bochum, Germany.

DOI: 10.1016/S1474-4422(24)00097-8

Link outs

Free resources

Medical:

https://medlineplus.gov/parkinsonsdisease.html

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1474...
https://www.clinicalkey.com/content/playBy/pii?v=S...

MeSH Terms: Humans, Parkinson Disease, Deferiprone, Antiparkinson Agents, Iron Chelating Agents, Pyridones, Negative Results, Randomized Controlled Trials as Topic